BCRB 2018

Example 1: Target driven lethality - EGFR

Tumors showing high EGFR expression

• NSCLC

40-80%

High expression generally associated with • Invasion • Metastasis • Late-stage disease • Chemo-/Radiotherapy resistance • Poor outcome

• Prostate

40-80%

• Gastric

33-74%

• Breast

14-91%

• Colorectal

25-77%

• Pancreatic

30-50%

• Ovarian

35-70%

• Bladder

31-48%

• Renal cell

50-90%

• H&N

80-100%

• Glioma

40-63%

• Esophageal

43-89%